Why Valeant Pharmaceuticals Intl Inc. Will Fail to Re-Invent Itself

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) had a horrible year, and I believe the stock is far from rallying.

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) had an abysmal year as the stock plummeted 86%. The company wants to re-invent itself to become a dominant player in the pharmaceutical scene again.

There were huge changes made this year as ex-CEO Michael Pearson stepped out and Joseph Papa stepped in. Joseph Papa is an excellent choice as the new CEO, and he’s got a ton of incentive to bring the company out of the gutter, but I believe he’s in way over his head. Valeant has severely damaged its reputation with investors across the globe, and I don’t believe anything can reverse what has already happened.

As Warren Buffett once said, “It takes 20 years to build a reputation and five minutes to ruin it.”. To say Valeant’s reputation has been ruined is an understatement.

The company has faced so many scandals and endured so many short attacks that even the most contrarian of investors are avoiding this stock like the plague. Charlie Munger, Warren Buffett’s right-hand man, even went as far as to call the company a “sewer.” These are strong words put forth by the guru, but I believe he’s right on the spot with his statement.

There are many contrarian investors that are looking to gain a quick profit by trying to get into Valeant. But there doesn’t appear to be a bottom, and the upside may be limited considering the company’s ruined reputation.

Activist investor Bill Ackman is now on the board of directors, and he’s still fully invested, even after the massive decline the stock faced over the past year and a half. Don’t follow Ackman into this one. Most of his original investment is already gone, and he’s just trying to recover some of his losses, but I don’t believe he’ll be successful.

Valeant still has $8 billion worth of debt and will need to sell its non-core assets at a loss. Buying high and selling low is never a good strategy to make money, and I believe the company will remain on damage control for the next few years before the stock can start moving higher.

Even if you’re a believer in Bill Ackman and the new CEO Joseph Papa, any upside in 2017 will be very modest, and there’s still the risk of a further correction as more disappointing earnings reports come in. There is also the risk of having more scandals should there be any shady findings from investigations going forward.

If you’re a contrarian investor, then steer clear of Valeant. Its reputation is permanently damaged, and it’s not going to soar anytime soon. There’s still a huge mess that Michael Pearson left, and it won’t be cleaned up anytime soon.

I have one simple rule. If there’s any sign of shady activity in a company’s history, then that makes the stock an automatic sell. Don’t even think about picking up share in Valeant unless you’re willing to lose it all.

Fool contributor Joey Frenette has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Colored pins on calendar showing a month
Dividend Stocks

This Dividend Stock Pays 5.1% and Sends Cash Every Month

This TSX stock offers reliable monthly dividend payments and yields over 5%. Moreover, it is likely to sustain its payouts.

Read more »

Real estate investment concept with person pointing on growth graph and coin stacking to get profit from property
Stocks for Beginners

1 Defensive TSX Stock I’d Buy Before More Market Volatility

Volatility can make flashy growth stocks fade fast, but defensive dividend payers like ATCO can look stronger when markets get…

Read more »

person enjoys shower of confetti outside
Stocks for Beginners

Why These 2 Canadian Stocks Could Be Huge Winners This Year

Two TSX growth stocks are riding hot themes — AI infrastructure and silver — with fresh results that keep the…

Read more »

Investor reading the newspaper
Dividend Stocks

3 Dividend Stocks That Belong in Almost Every Investor’s Portfolio

These three Canadian dividend stocks are simply among the best the TSX has to offer. No matter an investor's risk…

Read more »

Concept of multiple streams of income
Dividend Stocks

3 Canadian Blue-Chip Stocks to Hold Through 2026 and Beyond

Given their solid underlying businesses, disciplined capital allocation, and healthy growth prospects, these three Canadian blue-chip stocks offer attractive buying…

Read more »

semiconductor chip etching
Tech Stocks

This Stellar Canadian Stock Is Up 341% This Past Year and There’s More Growth Ahead

This Canadian stock has surged approximately 341%. Moroever, the stock has more growth ahead driven by AI-led tailwinds.

Read more »

shopper carries paper bags with purchases
Dividend Stocks

This 5.3% Dividend Stock is My Go-To for Cash Flow Planning

RioCan REIT (TSX:REI.UN) delivers monthly 5.3% dividends for smooth cash flow, paid on the 6th or the 8th of each…

Read more »

some REITs give investors exposure to commercial real estate
Bank Stocks

This 7.2% Yield Dividend Stock Has Been Quiet – but It Could Be Poised to Move in 2026

This under-the-radar dividend stock could be gearing up for a stronger move in 2026 and beyond.

Read more »